GHENT, Belgium, 16 January 2018 – Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of shareholdings from Van Herk Investments B.V. on 15 January 2018.
Van Herk Investments B.V. notified Ablynx that it has crossed the 10% threshold on 12 January 2018 and now holds 7,629,229 voting securites of Ablynx, representing 10.21% of the current 74,720,644 outstanding voting rights of Ablynx (versus 9.99% notified previously on 11 October 2017).
The notification contains the following information:
- Reason for the notification: acquisition or disposal of voting securities or voting rights
- Notification by: a parent undertaking or a controlling person
- Persons subject to the notification requirement: Mr. A. van Herk, Van Herk Investments B.V.
- Transaction date: 12 January 2018
- Threshold that is crossed: 10%
- Denominator: 74,720,644
- Details of the notification: Van Herk Investments B.V. holds 7,629,229 voting securities of Ablynx
- Chain of controlled undertakings through which the holding is effectively being held: Van Herk Investments B.V. is controlled by Mr. A. van Herk in accordance with Articles 5 and 7 of the Dutch Companies Code.
A full version of the transparency notification is available on Ablynx website, under the section Investors.
The articles of the association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights.
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
Follow us on Twitter @AblynxABLX
Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700